Compare MBBC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | TVRD |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 34.1M |
| IPO Year | N/A | N/A |
| Metric | MBBC | TVRD |
|---|---|---|
| Price | $14.00 | $3.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 1.9K | ★ 42.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.94 | $3.50 |
| 52 Week High | $14.64 | $43.65 |
| Indicator | MBBC | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 48.34 |
| Support Level | $10.05 | $3.81 |
| Resistance Level | N/A | $4.45 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 66.14 | 57.04 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.